European Journal of Internal Medicine
Volume 18, Issue 1 , Pages 18-25 , January 2007

Thiazolidinediones for the treatment of type 2 diabetes

  • J.W.F. Elte

      Affiliations

    • Sint Franciscus Gasthuis, Department of Internal Medicine, Kleiweg 500, 3045 PM Rotterdam, The Netherlands
    • Corresponding Author InformationCorresponding author. Tel.: +31 104616094; fax: +31 104612692.
    • ,
  • J.F. Blicklé

      Affiliations

    • Service de Médicine Interne, Diabète et Maladies Métaboliques, Hôpitaux Universitaires de Strasbourg, 67091 STRASBOURG Cedex, France

Received 8 May 2006 ,Revised 1 September 2006 ,Accepted 19 September 2006.

References 

  1. Reaven GM. Role of insulin resistance in human disease. Diabetes. 1988;37:1595–1607
  2. UK prospective diabetes study (UKPDS) group. Overview of 6 years therapy of type 2 diabetes: a progressive disease. Diabetes. 1995;44:1249–1250
  3. UK prospective diabetes study (UKPDS) group. Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–853
  4. UK prospective diabetes study (UKPDS) group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854–865
  5. Buchanan TA, Xiang AH, Peters RK, Kjos SL, Marroquin A, Goico J, et al. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes. 2002;51:2796–2803
  6. Ovalle F, Bell DSH. Clinical evidence of thiazolidinedione-induced improvement of pancreatic β-cell function in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2002;4:56–59
  7. Suwattee P, DeSouza C, Asnani S, Gilling L, Fonseca VA. Cardiovascular effects of thiazolidinediones. Endocrinologist. 2002;12:126–134
  8. Dormandy JA, Charbonnel B, Eckland DJA, Erdmann E, Massi-Benetti M, Moules IK, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomized controlled trial. Lancet. 2005;366:1279–1289
  9. Barman-Balfour JA, Plosker GL. Rosiglitazone. Drugs. 1999;57:921–930
  10. Gillies PS, Dunn CJ. Pioglitazone. Drugs. 2000;60:333–343
  11. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferators-activated receptor γ (PPARγ). J Biol Chem. 1995;270:12953–12956
  12. Vamecq J, Latruffe N. Peroxisome proliferators-activated receptors (PPARs) and their implications in diseases. Curr Opin Endocrinol Diabetes. 2000;7:8–18
  13. Tan MH. How pioglitazone affects glucose and lipid metabolism. Exp Clin Endocrinol Diabetes. 2000;108(suppl 2):S224–S233
  14. Tan MH, Baksi A, Krahulec B, Kubalski P, Stankiewicz A, Urquhart R, et al. Comparison of pioglitazone and gliclazide in sustaining glycemic control over 2 years in patients with type 2 diabetes. Diabetes Care. 2005;28:544–550
  15. Hanefeld M, et al. on behalf of the QUARTET Study Group One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes. Diabetes Care. 2004;27:141–147
  16. Khan MA, St. Peter JV, Xue JL. A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone. Diabetes Care. 2002;25:708–711
  17. van Wijk JPH, de Koning EJP, Castro Cabezas M, Rabelink TJ. Rosiglitazone improves postprandial triglyceride and free fatty acid metabolism in type 2 diabetes. Diabetes Care. 2005;28:844–849
  18. Goldberg RB, Kendall DM, Deeg MA, Buse JB, Zagar AJ, Pinaire JA, et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care. 2005;28:1547–1554
  19. Raji A, Seely EW, Bekins SA, Williams GH, Simonson DC. Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients. Diabetes Care. 2003;26:172–178
  20. Bennett SMA, Agrawal A, Elashat H. Rosiglitazone improves insulin sensitivity, glucose tolerance and ambulatory blood pressure in subjects with impaired glucose tolerance. Diabet Med. 2004;21:415–422
  21. Sarafidis PA, Lasaridis AN, Nilsson PM, Pagkalos EM, Hitoglou-Makedou AD, Pliakos CI, et al. Ambulatory blood pressure reduction after rosiglitazone treatment in patients with type 2 diabetes and hypertension correlates with insulin sensitivity increase. J Hypertens. 2004;22:1769–1777
  22. St John Sutton MJ, Rendell M, Dandona P, Dole JF, Murphy K, Patwardhan R, et al. A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes. Diabetes Care. 2002;25:2058–2064
  23. Bakris G, Viberti G, Weston WM, Heise M, Porter LE, Freed MI. Rosiglitazone reduces urinary albumin excretion in type II diabetes. J Hum Hypertens. 2003;17:7–12
  24. Lebovitz HE, Dole JF, Patwardhan R, Rappaport EB, Freed MI. for the rosiglitazone clinical trials study group. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab. 2001;86:280–288
  25. Freed M, Fuell D, Menci L, Heise M, Goldstein B. Effect of combination therapy with rosiglitazone and glibenclamide on PAI-1 antigen, PAI-1 activity, and tPA in patients with type 2 diabetes (Abstract). Diabetologia. 2000;43(Suppl. 1):A267;poster 1024
  26. Miyazaki Y, Mahankali A, Wajcberg E, Bajaj M, Mandarino LJ, DeFronzo RA. Effects of pioglitazone on circulating adipocytokine levels and insulin sensitivity in Type 2 diabetic patients. J Clin Endocrinol Metab. 2004;89:4312–4319
  27. Haffner SM, Greenberg AS, Weston WM, Chen H, Williams K, Fred MI. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation. 2002;106:679–684
  28. Miyazaki Y, Mahankali A, Matsuda M, Mahankali S, Hardies J, Cusi K, et al. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab. 2002;87:2784–2791
  29. Bays H, Mandarino L, DeFronzo R. Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach. J Clin Endocrinol Metab. 2004;89:463–478
  30. Minamikawa J, Tanaka S, Yamauchi M, Inoue D, Koshiyama H. Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab. 1998;83:1818–1820
  31. Koshiyama H, Shimono D, Kuwamura N, Minamikawa J, Nakamura Y. Inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab. 2001;86:3452–3456
  32. Sidhu JS, Kaposzta Z, Markus HS, Kaski JC. Effect of rosiglitazone on common carotid intima-media thickness progression in coronary artery disease patients without diabetes mellitus. Arterioscler Thromb Vasc Biol. 2004;24:930–934
  33. Nakamura T, Matsuda T, Kawagoe Y, Ogawa H, Takahashi Y, Sekizuka K, et al. Effect of pioglitazone on carotid intima-media thickness and arterial stiffness in type 2 diabetic nephropathy patients. Metabolism. 2004;53:1382–1386
  34. Langenfeld MR, Forst T, Hohnberg C, Kann P, Lübben G, Konrad T, et al. Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus. Results from a controlled randomized study. Circulation. 2005;111:2525–2531
  35. Pfützner A, Marx N, Lübben G, Langenfeld M, Walcher D, Konrad T, et al. Improvement of cardiovascular risk markers by pioglitazone is independent from glycemiuc control. J Am Coll Cardiol. 2005;45:1925–1931
  36. Choi D, Kim S-K, Choi S-H, Ko YG, Ahn CW, Jang Y, et al. Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes. Diabetes Care. 2004;27:2654–2660
  37. Osman A, Otero J, Brizolara A, Waxman S, Stouffer G, Fitzgerald P, et al. Effect of rosiglitazone on restenosis after coronary stenting in patients with type 2 diabetes. Am Heart J. 2004;147:21–25
  38. Marx N, Wöhrle JH, Nusser T, Walcher D, Rinker A, Hombach V, et al. Pioglitazone reduces neointima volume after coronary stent implantation. A randomized, placebo-controlled, double-blind trial in nondiabetic patients. Circulation. 2005;112:2792–2798
  39. Wang GM, Wei J, Guan Y, Jin N, Mao J, Wang X. Peroxisome proliferator-activated receptor-y agonist rosiglitazone reduces clinical inflammatory responses in type 2 diabetes with coronary artery disease after coronary angioplasty. Metab Clin Exp. 2005;54:590–597
  40. Smith SA, Lister CA, Toseland CDN, Buckingham RE. Rosiglitazone prevents the onset of hyperglycaemia and proteinuria in the Zucker diabetic fatty rat. Diabetes Obes Metab. 2000;2:363–372
  41. Ozawa S, Takizawa M, Itoh E, Katsuta H, Tanaka T, Yamaguchi S, et al. The protective effect of the long-term treatment by pioglitazone on the insulin secretory capacity and β cell mass in obese diabetic db/db mice. Diabetes. 2002;51(suppl 2):A 361;poster 1476-P
  42. Porter LE, Freed MI, Jones NP. Rosiglitazone reduces proinsulin/insulin ratio and improves β-cell function in type 2 diabetes. Diabetologia. 2000;43(suppl 1):A192;poster 737
  43. Rosenstock J for the pioglitazone HCI study group. Improved insulin sensitivity and beta cell responsivity suggested by homa analysis of pioglitazone therapy. Diabetologia. 2000;43(suppl 1):A192;poster 738
  44. Matthews DR. Insulin resistance and β-cell function — a clinical perspective. Diabetes Obes Metab. 2001;3(suppl. 1):S28–S33
  45. Miyazaki Y, Matsuda M, DeFronzo RA. Dose–response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes. Diabetes Care. 2002;25:517–523
  46. Juhl CB, Hollingdal M, Pørksen N, Prange A, Lönnqvist F, Schmitz O. Influence of rosiglitazone treatment on β-cell function in type 2 diabetes: evidence of an increased ability of glucose to entrain high-frequency insulin pulsatility. J Clin Endocrinol Metab. 2003;88(8):3794–3800
  47. Leiter LA. β-cell preservation: a potential role for thiazolidinediones to improve clinical care in type 2 diabetes. Diabet Med. 2005;22:963–972
  48. Yki-Järvinen H. The PROactive study: some answers, many questions. Lancet. 2005;366:1241–1242
  49. Fonseca V, Jawa A, Asnani S. Commentary: the PROactive study — the glass is half full. J Clin Endocrinol Metab. 2006;91:25–27
  50. Ceriello A. PROactive study : (r)evolution in the therapy of diabetes ?. Diabet Med. 2005;22:1463–1464
  51. Scheen AJ. Hepatotoxicity with thiazolidinediones. Is it a class effect?. Drug Safety. 2001;24:873–888
  52. Nesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, Horton ES, et al. Thiazolidinedione use, fluid retention, and congestive heart failure. Circulation. 2003;108:2941–2948
  53. Nakamura T, Funahashi T, Yamashita S, Nishida M, Nishida Y, Takahashi M, et al. Thiazolidinedione derivative improves fat distribution and multiple risk factors in subjects with visceral fat accumulation-double-blind placebo-controlled trial. Diabetes Res Clin Pract. 2001;54:181–190
  54. IDF . A desktop guide to type 2 diabetes. Diabet Med. 1999;16:716–730
  55. Rosenstock J, Sugimoto D, Strange P, Stewart J, Soltes-Rak E, Dailey G. Triple therapy in type 2 diabetes (T2DM): benefits of insulin glargine (GLAR) over rosiglitazone (RSG) added to combination therapy of sulfonylurea plus metformin (SU+MET) in insulin-naïve patients. Diabetes. 2004;(suppl. 3):poster 609
  56. Neeser K, Lübben G, Siebert U, Schramm W. Cost effectiveness of combination therapy with Pioglitazone for type 2 diabetes mellitus from a German statutory healthcare perspective. PharmacoEconomics. 2004;22:321–341
  57. Henriksson F. Applications of economic models in healthcare. The introduction of Pioglitazone in Sweden. PharmacoEconomics. 2002;20(Suppl 1):43–53
  58. Coyle D, Palmer AJ, Tam R. Economic evaluation of Pioglitazone hydrochloride in the management of type 2 diabetes mellitus in Canada. PharmacoEconomics. 2002;20(Suppl 1):31–42
  59. Kalkesar I, Iyer S, Mody R, Rajagopalan R, Kavookjian J. Utilization and costs for compliant patients initiating therapy with Pioglitazone or Rosiglitazone versus insulin in a Medicaid fee-for-service population. J Manag Care Pharm. 2006;12:121–129
  60. Bottomley J, Palmer AJ, Williams R, Dormandy J, Massi-Benedetti M. PROactive 03: pioglitazone, type 2 diabetes and reducing macrovascular events — economic implications?. Br J Diabetes Vasc Dis. 2006;6:63–70
  61. Kendall DM. Thiazolidinediones. The case for early use. Diabetes Care. 2006;29:154–157
  62. Ovalle F, Ovalle-Berúmen JF. Thiazolidinediones: a review of their benefits and risks. South Med J. 2002;95:1188–1194

PII: S0953-6205(06)00257-3

doi: 10.1016/j.ejim.2006.09.007

European Journal of Internal Medicine
Volume 18, Issue 1 , Pages 18-25 , January 2007

Article Tools

* Image Usage & Resolution